Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
250 participants
INTERVENTIONAL
2022-03-14
2022-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparing Two-time Points of Thyroid Hormone Replacement During the Holy Month of Ramadan
NCT03988517
Impact of Increasing Levothyroxine Dose in Ramadan for UAE Patients With Hypothyroidism
NCT06135948
Comparison Between Variable Time Regimen of Dosing L-Thyroxine for Treatment Hypothyroid Fasting Ramadan
NCT05918497
Evaluation of Evening Versus Morning Levothyroxine Intake in Elderly
NCT03614988
Long-Term Efficacy and Safety of Once-Weekly Levothyroxine Regimen in Hypothyroid Patients
NCT07133295
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A prospective, randomized, open label, multicenter Study. The first group will be will be instructed to take their L-thyroxin dose as per current guidlines at breaking of fast time (sunset) with sip of water then wait 30-60 minutes to consume Iftar meal. The second group (pre-Fajer prayer), patients are going to be instructed to take L-thyroxin dose immediately before start of fast, i.e. Alfajer (dawn) regardless of Suhoor time. The values of Thyroid stimulating hormone (TSH) will be measured two weeks before Ramadan, and 2-4 weeks after Ramadan for comparison.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pre-Iftar (Breaking the fast)
To take thyroxine at breaking of fast with sip of water then wait 30-60 miuntes to eat iftar (breakfast).
L-Thyroxine time B (5-15 minutes Before dawn)
Taking thyroxine at two different time points in relation to fasting and food intake; just before dawn and start of fast compared to the usual timing of 30-60minutes after the sunset breakfast meal.
Pre-Fajr (Starting the fast)
To take thyroxine immediately before start of fast at predawn time regardless of last meal time.
L-Thyroxine time B (5-15 minutes Before dawn)
Taking thyroxine at two different time points in relation to fasting and food intake; just before dawn and start of fast compared to the usual timing of 30-60minutes after the sunset breakfast meal.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
L-Thyroxine time B (5-15 minutes Before dawn)
Taking thyroxine at two different time points in relation to fasting and food intake; just before dawn and start of fast compared to the usual timing of 30-60minutes after the sunset breakfast meal.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with controlled thyroid function for last 3 months on same dose of levothyroxine.
Exclusion Criteria
* Uncontrolled thyroid function test three months prior Ramadan.
* Thyroid cancer patients who require suppressed TSH.
* Central Hypothyroidism, patient with acute illness.
* Patients diagnosed with malabsorption i.e., Celiac Disease, Short bowel, Bariatric surgeries
* Use of certain Medications like systemic glucocorticoids, activated charcoal, sucralfate, aluminum hydroxide antacid, bile acid sequestrants, iron, calcium carbonate, PPI, rifampicin, and antiepileptic medications
* Renal or hepatic disease:
* Creatinine clearance \<0.6 ml/s or serum creatinine ≥200 μmol/l
* Alanine transferase ≥2.5 times the upper limit of normal
* Active liver disease including jaundice, chronic hepatitis, previous liver transplant
* Unwillingness to be randomized or to sign informed consent
* Known Psychiatric Disorders
* Known uncontrolled substance abuse or alcoholism
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
King Abdullah International Medical Research Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Reem Alamoudi
Jeddah, , Saudi Arabia
KingAbullahIMRC
Jeddah, , Saudi Arabia
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ICT22J-001-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.